4.8 Article

Androgen insensitivity syndrome

Journal

LANCET
Volume 380, Issue 9851, Pages 1419-1428

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)60071-3

Keywords

-

Funding

  1. Pfizer
  2. Novo Nordisk
  3. Ferring
  4. Merck Serono
  5. Ipsen
  6. Newlife
  7. EC within EuroDSD [201444]
  8. Medical Research Council [G1100236] Funding Source: researchfish
  9. MRC [G1100236] Funding Source: UKRI

Ask authors/readers for more resources

Androgen insensitivity syndrome in its complete form is a disorder of hormone resistance characterised by a female phenotype in an individual with an XY karyotype and testes producing age-appropriate normal concentrations of androgens. Pathogenesis is the result of mutations in the X-linked androgen receptor gene, which encodes for the ligand-activated androgen receptor-a transcription factor and member of the nuclear receptor superfamily. This Seminar describes the clinical manifestations of androgen insensitivity syndrome from infancy to adulthood, reviews the mechanism of androgen action, and shows examples of how mutations of the androgen receptor gene cause the syndrome. Management of androgen insensitivity syndrome should be undertaken by a multidisciplinary team and include gonadectomy to avoid gonad tumours in later life, appropriate sex-hormone replacement at puberty and beyond, and an emphasis on openness in disclosure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available